How Senphonix Won an NSF STTR Phase I for SleeveSense | BW&CO
Quick Answer
Senphonix, Inc., a Tucson-based medical technology company, won a Small Business Technology Transfer (STTR) Phase I award from the U.S. National Science Foundation through America's Seed Fund to advance SleeveSense, a wearable that continuously monitors patient vital signs over days, weeks, or months. BW&CO worked alongside the Senphonix team on the application, providing project management, funding strategy, proposal writing, and compliance and administrative support. The award is being executed in partnership with the University of Arizona.
The company and the technology
Senphonix is developing SleeveSense, a patent-pending wearable sleeve designed to stream multiple vital signs continuously, both during a hospital stay and after the patient goes home. The clinical problem it targets is well understood by anyone who has worked a hospital floor: vitals are typically captured as periodic spot checks, and nurses can spend 20 percent or more of a shift taking them manually. Continuous monitoring is intended to remove that manual burden, surface signs of patient deterioration earlier, and give clinicians visibility into the post-discharge window that currently goes dark.
The demand signal was already strong before the federal award. In a national survey of practicing nurses, 98 percent (n=402) said they would support SleeveSense if it saves some of the time spent on manual vitals. In a separate study, 94 percent of hospital CFOs (n=457) indicated intent to support adoption, particularly where it drives nursing efficiency, better outcomes, and readmission avoidance.
Senphonix had also already proven it could attract non-federal support. Matching grant funding from the Arizona Commerce Authority, through the WearTech Applied Research Center, backed the company's early design work and carried it from concept to working prototype. The question was how to fund the next stage, the hard engineering required to make the device perform reliably in a real hospital environment and to move it toward manufacturing at scale, without giving up equity to do it.
Why NSF, and why STTR
NSF's America's Seed Fund is a strong fit for deep technology that still carries meaningful technical risk. NSF is explicit that the program is meant for work requiring substantial high-risk research and development, not straightforward engineering or incremental product development. The remaining work on SleeveSense, specifically the wireless and radio-frequency systems, the antenna, and the power architecture behaving predictably inside a live clinical environment, sits squarely in that category.
The STTR mechanism, rather than SBIR, was the right structural fit because the work depends on a genuine research partnership. Senphonix is working with Dr. Philipp Gutruf, Associate Professor of Biomedical Engineering at the University of Arizona, whose lab brings expertise in biosymbiotic electronics to the SleeveSense platform. STTR is built for exactly this arrangement, and it carries structural requirements that SBIR does not.
What makes an NSF STTR Phase I harder than it looks
Founders frequently underestimate this application. Several things have to be true at once, and each one has its own timeline:
The Project Pitch gate. NSF requires a Project Pitch before a full proposal can be submitted. Only pitches NSF determines to be a good fit receive an invitation, and a company may submit at most two Project Pitches in any 12-month period. This is distinctive to NSF among SBIR/STTR agencies, and the review turnaround adds lead time well before the full proposal deadline.
The 40/30 work split. Under STTR, the small business must perform at least 40 percent of the research and development and the single partnering research institution at least 30 percent, measured by budget. Deviation is not permitted. Budget percentages and narrative percentages have to match exactly, and mismatches are a compliance flag.
The allocation of rights agreement. STTR requires a written intellectual property agreement between the small business and the research institution covering IP ownership and follow-on research, development, and commercialization rights. University technology transfer offices move at their own pace, and a negotiation started late can delay or cost an award.
The competitive rate. Historical NSF SBIR/STTR Phase I funding rates run between 10 and 20 percent. A proposal that is merely competent does not clear.
Everything running in parallel. Registrations, the university subaward, budget construction, the IP agreement, the technical narrative, and the commercialization case all have to converge on one date, while the founding team is also building the product and preparing for clinical testing.
How BW&CO worked with Senphonix
Two BW&CO team members led the engagement.
Kristian ran project management and funding strategy, and contributed to writing the proposal itself. That meant sequencing the work backward from the submission date, keeping the company, the university partner, and the proposal components moving on the same clock, and connecting the individual pieces into a single coherent application. On a multi-party STTR, this coordination role is not administrative overhead. It is the difference between a package that holds together and one that reads like it was assembled by three groups that never spoke.
Barbara handled compliance and administration. Federal eligibility, registrations, and the structural requirements that govern an STTR submission are unforgiving, and they are also the part of the process founders are least equipped to absorb. Getting them right early is what keeps a technically excellent proposal from being sunk by something procedural.
The purpose of that division of labor is straightforward. A founding team preparing for clinical testing and a 2027 market entry has a limited number of hours, and the highest-value use of those hours is not learning federal proposal mechanics from scratch. BW&CO's role was to raise the probability of a win while giving the Senphonix team back the time the application would otherwise have consumed.
The result
Senphonix received an NSF STTR Phase I award under Award No. 2537968. The funding supports engineering to strengthen the wireless and radio-frequency systems of the patent-pending device and to move it from prototype toward a manufacturable product at scale, in partnership with the University of Arizona.
As Mike Haldane, Co-Founder and Co-CEO of Senphonix, put it when the award was announced, the award is significant validation of the critical needs SleeveSense will address, and NSF's support allows the company to further engineer the technology as it prepares to go to market in 2027.
The capital is non-dilutive. Senphonix retained full ownership of the company and of its technology while funding the next stage of development, and it now has a federal award on its record ahead of the clinical testing expected to begin in late 2026 or early 2027 and the FDA clearance pathway the company intends to pursue in early to mid-2027.
What founders can take from this
Three things generalize beyond this engagement.
State funding and federal funding are a sequence, not alternatives. Arizona Commerce Authority support carried Senphonix from concept to prototype, which in turn gave the company the technical evidence a federal reviewer wants to see. Companies that treat early state and regional programs as a stepping stone tend to arrive at the federal stage with a stronger case than companies that go straight for the larger award.
Choosing the right mechanism is a strategic decision, not a formality. SBIR and STTR are not interchangeable. When the work genuinely depends on a university lab's expertise or facilities, STTR's structure fits in a way SBIR's subcontracting limits do not. Getting that decision wrong early can force a restructure late.
The proposal is only one of the things that has to be finished on time. Registrations, subaward paperwork, and the allocation of rights agreement run on institutional timelines that no amount of late effort can compress. The applications that fail on procedure rather than merit are usually the ones that started those threads last instead of first.
Frequently asked questions
What is the difference between an NSF SBIR and an NSF STTR award?
Both are part of America's Seed Fund and both provide non-dilutive funding to small businesses, but STTR requires a formal partnership with a research institution. Under STTR, the small business must perform at least 40 percent of the research and development and a single partnering research institution must perform at least 30 percent, measured by budget. SBIR has no research institution requirement and instead caps how much work can be subcontracted. STTR is the better fit when the project genuinely depends on a university lab's expertise, facilities, or licensed intellectual property.
How much is an NSF STTR Phase I award worth?
Under NSF's current solicitation, Phase I awards are up to $305,000 and Phase II awards are up to $1,250,000. NSF does not require matching funds on base awards, and the funding is non-dilutive, meaning the company gives up no equity and retains control of its technology and research direction.
Do you need a university partner to apply for an NSF STTR?
Yes. An STTR Phase I proposal must include an eligible research institution as a subawardee on the project budget. That institution is typically a not-for-profit college or university, or a federally funded research and development center. The partnership has to be substantive. Reviewers can tell when a research institution has been added to satisfy a rule rather than to do real work.
What is the NSF Project Pitch and why does it matter?
The Project Pitch is a mandatory first step before an NSF SBIR or STTR full proposal. NSF reviews the pitch and only invites companies it determines to be a good fit for the program's objectives to submit a full proposal. A company may submit at most two Project Pitches in any 12-month period. Because the review adds lead time before a proposal can even be submitted, the pitch has to be planned for separately from the full proposal deadline, and a weak pitch can cost a company a cycle.
What is an allocation of rights agreement?
It is a written agreement, required under STTR, negotiated between the small business and its partnering research institution that allocates intellectual property rights and the rights to carry out follow-on research, development, or commercialization. Typically the small business retains commercialization rights and the university retains publication rights, but the terms are negotiable. University technology transfer offices are rarely fast, so this negotiation should begin early rather than in the final weeks before a deadline.
How competitive is an NSF SBIR or STTR Phase I award?
Historical NSF SBIR/STTR Phase I funding rates run between 10 and 20 percent. NSF also states plainly that the program is intended for technologies requiring substantial high-risk research and development, not straightforward engineering or incremental product development, which means a technically sound project can still be declined for being insufficiently risky or insufficiently novel.
Can a company that already received state funding still apply for NSF?
Yes, and prior state or regional support is often an asset rather than an obstacle. Early funding that takes a technology from concept to working prototype produces exactly the kind of technical evidence federal reviewers look for. Senphonix received matching grant funding from the Arizona Commerce Authority through the WearTech Applied Research Center before pursuing its NSF award.
Work with BW&CO
BW&CO helps deep technology, medtech, and biotech founders win non-dilutive federal funding without turning the application into a second full-time job. We handle the strategy, the proposal, and the compliance so founders can keep building. Innovation Funding Simplified.
If you are developing a technology that depends on a university research partnership and want an honest read on whether NSF SBIR or STTR is the right path, contact us for a funding fit assessment.